BETd-260 (ZBC260, BETd260) is a PROTAC BET degrader, through the ligand linkage of Cereblon and BET, BETd-260 potently inhibits cell viability and strongly induces apoptosis in hepatocellular carcinoma (HCC) cells. BETd-260 has been shown to be active against leukemia cells in vitro and stem-like cells in vivo. HJB97 can be attached to the ligand of the E3 ubiquitin ligase VHL. BETd-260 is currently in clinical development for the treatment of cancer and inflammatory diseases.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.